Phase 2 Trials
LSD Therapy
LSD (lysergic acid diethylamide) is being researched for anxiety disorders and generalized anxiety. Definium Therapeutics (formerly MindMed) is leading Phase 2 trials with their MM-120 formulation.
50Clinical Trials
1Companies
0Legal States
FDA StatusPhase 2 Trials
Legal PathwayFDA approval pathway (federal)
Also Known Aslysergic acid diethylamide, acid, MM120
Legal Status by State
View full legal tracker →Fully Operational
Legal, Launching
Decriminalized
Active Legislation
Research Only
No Activity
Clinical Trials
9 trials currently recruiting
Phase 121
Phase 214
Phase 34
Active, Not Recruiting·Phase 3·LSD
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Definium Therapeutics US, Inc.
Generalized Anxiety Disorder
Active, Not Recruiting·Early Phase 1·LSD
LSD Occupancy of the Serotonin 2A Receptor in the Human Brain
Rigshospitalet, Denmark
Basic Science
Approved for Marketing·N/A·LSD
BMN 110 US Expanded Access Program
BioMarin Pharmaceutical
Mucopolysaccharidosis IVAMorquio A SyndromeMPS IVA
Completed·Early Phase 1·LSD
Drug Effects on Mood and Behavior - Expectancy
University of Chicago
LSD
Completed·Early Phase 1·LSD
Mood Effects of Serotonin Agonists: Depression
University of Chicago
LSDMajor Depressive DisorderDepression
Completed·N/A·LSD
Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy
Tatiana Aboulafia Brakha
Depression, Anxiety
Companies & Research
Organizations developing LSD-based therapies